Protocol Ledger

Federal / Public Agency · Consolidated Sponsor Hub

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Clinical Trials & FDA Approval Profile

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (Global / Institutional) sponsors 28 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 17 active protocols (9 recruiting now), 4 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)25.0%
Median Closed Enrollment vs National (145 pts)59 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)28
Active Pipeline (Recruiting Now)17 (9)
Completed vs Stopped Early4 / 7 (25.0%)
Median Closed Actual Enrollment59 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hospital Research SiteLocationShared Protocols
NIH Clinical CenterBethesda, MD14
Columbia University Irving Medical CenterNew York, NY8
UCSF Medical Center and Helen Diller Cancer CenterSan Francisco, CA8

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT05832229Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United StatesPhase IIRECRUITING
NCT07142252Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes MellitusPhase IIRECRUITING
NCT03929601Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 DiabetesPhase IIACTIVE NOT RECRUITING
NCT05743244Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)Phase IIACTIVE NOT RECRUITING
NCT04291703STOP-T1D Low-Dose (ATG)Phase IITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Interactive Dossier, benchmark peers in Endocrinology, Obesity, and Metabolic, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI